Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Ethacizine→

Ethacizine Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
33414-33-4
Molecular formula
C22H27N3O3S
Molecular weight
413.54 g/mol
Drug class
Class IC antiarrhythmicvoltage-gated sodium-channel blocker
Mechanism of action
Blocks fast voltage-gated sodium channels in cardiac myocytes, slowing phase-0 depolarisation and conduction velocity. It can suppress abnormal atrial and ventricular impulse propagation but may be proarrhythmic in structural heart disease.
Indications / reported uses
  • Treatment of selected supraventricular and ventricular tachyarrhythmias in countries where ethacizine is authorised, under specialist ECG monitoring; use is highly jurisdiction-specific and not a general first-line antiarrhythmic indication

Sources: NLM MeSH — Ethacizine · PubMed — Ethacizine class IC antiarrhythmic · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Ethacizine Environmental Risk Assessment (ERA) (the Ethacizine ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.